Inventor · disambiguated record
Ming Yu
Also filed as: YU MING · YU MING-JIUE
26 granted patents·19 pending applications·52 citations·filing 2003–2024
94Inventor score
Top patents by PatentIndex Score
45 records- 0191US10100063B2Compounds that inhibit Mcl-1 proteinAMGEN INC·Filed 2016·Granted Oct 16, 2018·8 cites·12 claims
- 0288US9593129B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2016·Granted Mar 14, 2017·5 cites·18 claims
- 0388US9296736B2Piperidinone derivatives as MDM2 inhibitors for the treatment of cancerAMGEN INC·Filed 2014·Granted Mar 29, 2016·7 cites·13 claims
- 0487US2024300892A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2023·Application pending·0 cites
- 0586US8030354B2Substituted biphenyl GPR40 modulatorsAMGEN INC·Filed 2008·Granted Oct 4, 2011·11 cites·96 claims
- 0683US8450522B2Conformationally constrained carboxylic acid derivatives useful for treating metabolic disordersBROWN SEAN P·Filed 2009·Granted May 28, 2013·9 cites·17 claims
- 0781US11306107B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2017·Granted Apr 19, 2022·2 cites·11 claims
- 0880US11014884B2Modulators of hemoglobinGLOBAL BLOOD THERAPEUTICS INC·Filed 2019·Granted May 25, 2021·2 cites·60 claims
- 0980US2022169611A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2022·Application pending·0 cites
- 1079US11254651B2Histone methyltransferase inhibitorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2017·Granted Feb 22, 2022·2 cites·20 claims
- 1176US11111243B2Azaindole compounds as histone methyltransferase inhibitorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2018·Granted Sep 7, 2021·1 cites·20 claims
- 1276US10826017B2Packaging assembly and preparation method thereof, and display deviceSHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECH CO LTD·Filed 2018·Granted Nov 3, 2020·1 cites·7 claims
- 1374US10836779B2Compounds that inhibit MCL-1 proteinAMGEN INC·Filed 2018·Granted Nov 17, 2020·0 cites·8 claims
- 1474US8680129B2Compounds, composition, methods, targets for cancer therapyYU MING·Filed 2010·Granted Mar 25, 2014·1 cites·1 claims
- 1574US2021179560A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2020·Application pending·0 cites
- 1673US8748462B2Spirocyclic GPR40 modulatorsBROWN SEAN P·Filed 2009·Granted Jun 10, 2014·2 cites·25 claims
- 1771US11566030B2Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activatorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2022·Granted Jan 31, 2023·0 cites·31 claims
- 1868US2023151016A1Pyrrolidine-pyrazoles as pyruvate kinase activatorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1967US2019062276A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2018·Application pending·0 cites
- 2065US2014011796A1Piperidinone derivatives as mdm2 inhibitors for the treatment of cancerAMGEN INC·Filed 2013·Application pending·0 cites
- 2164US2017144971A1Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of CancerAMGEN INC·Filed 2017·Application pending·0 cites
- 2263US11713299B2Histone methyltransferase inhibitorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2020·Granted Aug 1, 2023·0 cites·28 claims
- 2363US2021371417A1Azaindole compounds as histone methyltransferase inhibitorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2462US2014163088A1Compounds, composition, methods, targets for cancer therapyYU MING·Filed 2014·Application pending·0 cites
- 2561US2025026763A1Egfr inhibitors and methods of use thereofAllorion Therapeutics Inc·Filed 2024·Application pending·0 cites
- 2661US2024228493A1Lrrk2 inhibitors and uses thereofNEURON23 ICN·Filed 2023·Application pending·0 cites
- 2761US2024208972A1Lrrk2 inhibitors and uses thereofNEURON23 INC·Filed 2023·Application pending·0 cites
- 2860US2024174647A1Kinase modulators and methods of use thereofNEURON23 INC·Filed 2023·Application pending·0 cites
- 2958US10829452B2Histone methyltransferase inhibitorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2017·Granted Nov 10, 2020·0 cites·16 claims
- 3057US2024408107A1Lactam pyrrolidine-pyrazoles as pyruvate kinase activatorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3156US10144746B2Bridged bicyclic kallikrein inhibitorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2017·Granted Dec 4, 2018·0 cites·17 claims
- 3256US2017081662A1Compounds, composition, methods, targets for cancer therapyYU MING·Filed 2016·Application pending·0 cites
- 3354US2023159538A1Pyrrolidine-pyrazoles as pyruvate kinase activatorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3453US9815853B2Bridged bicyclic kallikrein inhibitorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2016·Granted Nov 14, 2017·0 cites·16 claims
- 3552US2023278984A1Urea derivatives as pyruvate kinase activatorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3650US2024067655A1Kinase modulators and methods of use thereofNEURON23 INC·Filed 2021·Application pending·0 cites
- 3747US8022061B2N-aryl pyrazole compounds, compositions, and methods for their useAMGEN INC·Filed 2007·Granted Sep 20, 2011·0 cites·15 claims
- 3844US11661410B2Tricyclic compounds as histone methyltransferase inhibitorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2018·Granted May 30, 2023·0 cites·27 claims
- 3944US7034163B2Synthesis of pyrrolesUNIV TEXAS·Filed 2003·Granted Apr 25, 2006·1 cites·9 claims
- 4043US11584734B2Tricyclic compounds as histone methyltransferase inhibitorsGLOBAL BLOOD THERAPEUTICS INC·Filed 2018·Granted Feb 21, 2023·0 cites·45 claims
- 4142US10058849B2Metal complex catalyst, preparation method thereof, and use thereof in preparing D,L-mentholZHEJIANG NHU CO LTD·Filed 2016·Granted Aug 28, 2018·0 cites·10 claims
- 4241US2021359133A1Oxide thin-film transistor device and manufacturing method thereofSHENZHEN CHINA STAR OPTOELECTRONICS SEMICONDUCTOR DISPLAY TECH CO LTD·Filed 2019·Application pending·0 cites
- 4336US10829510B2Method for preparing sucralose-6-acetate in biphasic liquid-liquid systemZHEJIANG NHU CO LTD·Filed 2017·Granted Nov 10, 2020·0 cites·9 claims
- 4436US10065901B2Method for preparing optically active carbonyl compoundZHEJIANG NHU CO LTD·Filed 2016·Granted Sep 4, 2018·0 cites·18 claims
- 4531US8785468B2Phenylalanine amide derivatives useful for treating insulin-related diseases and conditionsDU XIAOHUI·Filed 2010·Granted Jul 22, 2014·0 cites·9 claims
Join the waitlist — get patent alerts
Get an alert when Ming Yu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →